Table 1.
Rates of progression of disease within 24 months (POD24) in studies of rituximab as first-line therapy for follicular lymphoma
| Study | Treatment | Number of patients | POD24 definition | POD24 rate (percentage of patients) |
|---|---|---|---|---|
| Trials without anti-CD20 maintenance therapy | ||||
| Hiddemann et al. (GLSG’00)[22] | CHOP vs. R-CHOP followed by treatment intensification or IFN-α maintenance | 428 | Treatment failure (resistance to initial therapy, progressive disease, or death) within 24 months from the start of treatment | ~ 37% vs. ~ 19% |
| Marcus et al. [27, 28] | CVP vs. R-CVP | 321 | Disease progression, relapse, or death within 24 months from study randomization | ~ 65% vs. ~ 35% |
| Herold et al. [29] | MCP vs. R-MCP + IFN maintenance | 358 | PFS (progression of disease or death from NHL) within 24 months of randomization | ~ 48% vs. ~ 15% |
| Salles et al. (GELA-GOELAMS FL2000) [30] | CHVP + IFN maintenance vs. R-CHVP + IFN maintenance | 358 | EFS (progression, relapse, start of new treatment, or death from any cause) within 24 months of randomization | 33% vs. 21% |
| Federico et al. (FOLL05) [71] | R-CVP vs. R-CHOP vs. R-FM | 504 | Treatment failure (less than PR, change of therapy after at least cycle 1, progressive disease or relapse, or death) within 24 months of study entry | 56% vs. 50% vs. 44% |
| Rummel et al. [72] | BR vs. R-CHOP | 514 | PFS (progression of disease, relapse after response, or death from any cause) within 24 months from first treatment | ~ 22% vs. ~ 40% |
| Trials with anti-CD20 maintenance therapy | ||||
| Bachy et al. (PRIMA) [20] | R-chemotherapy (R-CHOP, R-CVP, R-FCM) followed by (in responders) R-maintenance or observation for 2 years | 1135 | Death from any cause, disease relapse or progression, unplanned retreatment of lymphoma after initial management, or the date of last contact within 24 months from diagnosis | ~ 25% in the combined cohort |
| Fowler et al. (RELEVANCE) [32] | R-chemotherapy (R-CHOP, R-CVP, or R-bendamustine) followed by R-maintenance for 2 years vs. R-Len | 517 | 100 minus 2-year PFS rate |
13% (assessed by independent review committee) or 17% (investigator-assessed) R-chemotherapy 16% (assessed by independent review committee or investigator) R-LEN |
| Seymour et al. (GALLIUM) [25] | R/G-chemotherapy (R/G-CHOP, R/G-CVP, or R/G-bendamustine), followed (in responders) by R/G-maintenance for 2 years | 601 | Progressive disease or death due to progressive disease within 24 months of randomization to first-line treatment |
16% R-chemotherapy 9% G-chemotherapy |
| Jurinovic et al. (GLSG’00 and BCCA) [33] | R-CHOP and IFN-α maintenance (GLSG) or R-CVP followed by R-maintenance (BCCA) | 132 (GLSG) and 102 (BCCA) | Relapse or progression of FL within 24 months of starting 1st-line treatment | 17% (GLSG) and 23% (BCCA) |
BCCA British Columbia Cancer Agency, BR bendamustine and rituximab, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, CHVP cyclophosphamide, Adriamycin, etoposide, and prednisolone, CVP cyclophosphamide, vincristine, and prednisone, EFS event-free survival, FCM fludarabine, cyclophosphamide, and mitoxantrone, FM fludarabine and mitoxantrone, G obinutuzumab, GLSG German Low-Grade Lymphoma Study Group, IFN interferon, Len lenalidomide, MCP mitoxantrone, chlorambucil, and prednisolone, NHL non-Hodgkin lymphoma, PFS progression-free survival, PR partial response, R rituximab